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Abstract
Immunotherapies that induce durable immune control of chronic HIV infection may eliminate the need for life-long
dependence on drugs. We investigated a DNA vaccine formulated with a novel genetic adjuvant that stimulates immune
responses in the blood and gut for the ability to improve therapy in rhesus macaques chronically infected with SIV. Using
the SIV-macaque model for AIDS, we show that epidermal co-delivery of plasmids expressing SIV Gag, RT, Nef and Env, and
the mucosal adjuvant, heat-labile E. coli enterotoxin (LT), during antiretroviral therapy (ART) induced a substantial 2–4-log
fold reduction in mean virus burden in both the gut and blood when compared to unvaccinated controls and provided
durable protection from viral rebound and disease progression after the drug was discontinued. This effect was associated
with significant increases in IFN-c T cell responses in both the blood and gut and SIV-specific CD8+ T cells with dual TNF-a
and cytolytic effector functions in the blood. Importantly, a broader specificity in the T cell response seen in the gut, but not
the blood, significantly correlated with a reduction in virus production in mucosal tissues and a lower virus burden in
plasma. We conclude that immunizing with vaccines that induce immune responses in mucosal gut tissue could reduce
residual viral reservoirs during drug therapy and improve long-term treatment of HIV infection in humans.
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Introduction
Although antiretroviral drugs exert considerable control of HIV
infection, they do not eliminate virus in the tissues or fully restore
virus-specific immunity and interruption of therapy usually results
in viral rebound [1,2,3]. Because CD4+ and CD8+ T cells play a
critical role in controlling chronic HIV infection [4], the goal of
therapeutic vaccination is to stimulate these responses during
antiretroviral drug therapy (ART) and induce durable immune
control of the virus even after ART is discontinued. In this setting,
an effective therapeutic vaccine would free HIV-1 infected persons
from the complexities of continuous drug dosing, reduce exposure
to drugs and associated toxicities, and reduce the potential to
transmit virus.
Studies employing therapeutic immunization with peptide-
pulsed dendritic cells or PBMC [5,6], viral vectored vaccines
[7], or DNA vaccines [8,9] support this concept in that therapeutic
vaccination with these approaches has been shown to enhance
virus-specific T cell responses, reduce viral set-point after
withdrawing drugs, and slow or prevent disease progression in
SIV-infected macaques. Some of these approaches also had some
immunological impact and virological benefit in chronically HIV-
1 infected patients [10,11,12]. However, durable protection from
viral rebound after withdrawing ART has been more difficult to
achieve and the immune responses required for long term
protection from viral rebound and progression to AIDS after
stopping HAART are not yet defined. The gut associated
lymphoid tissue (GALT) is a primary reservoir of persistent virus
that is inadequately controlled by HAART [13,14]. Therapeutic
vaccines that stimulate mucosal immune responses in the gut could
provide a means to more effectively target and control viral
replication in this reservoir but to date the impact of a therapeutic
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vaccine on virus in the gut or other tissue reservoirs has not been
investigated.
DNA vaccines are potent inducers of virus-specific T cell
responses [15], and studies have shown that prophylactic DNA
vaccines, administered either alone or with recombinant viral
vaccines, can provide protection against challenges with avirulent
and homologous, pathogenic AIDS viruses [16,17,18,19,20,21].
Our laboratory previously showed significant prophylactic protec-
tion in the SIV model using particle mediated epidermal delivery
(PMED; gene gun) of a DNA vaccine [22]. In that study, PMED
DNA immunization induced SIV-specific antibody and CD8+ T
cell responses in the blood and also in the gut mucosa of
macaques. Importantly, despite modest responses in the blood, the
vaccine provided complete protection from a disseminated
infection in 4 of 7 animals following a high dose rectal challenge
with SIV/DeltaB670, a primary isolate that is neutralization
resistant [23] and heterologous to the vaccine. Protection following
a mucosal challenge in that study strongly indicated that the
mucosal responses induced by the PMED DNA vaccine likely
played a key role in preventing viral dissemination. In the present
study, we investigate the feasibility of administering a therapeutic
PMED DNA vaccine formulated with a mucosal adjuvant during
ART as a means to augment mucosal T cell responses and target
the persistent viral reservoir in the GALT.
Here we show that immunization of chronically SIV-infected
macaques with a therapeutic SIV DNA vaccine, together with
a plasmid expressing the potent mucosal adjuvant, the heat-labile
enterotoxin from E. coli (LT), during antiretroviral therapy (ART)
increased systemic and mucosal T cell responses, significantly
reduced virus burden in the blood and gut tissues, and pro-
vided durable protection from viral rebound and progression to
disease after stopping ART in the majority of animals that
responded well to antiretroviral drugs. These studies also show, for
the first time, that a mucosally targeted therapeutic vaccine can
induce responses unique to the gut that correlate with therapeutic
efficacy.
Results
Study design
An effective therapeutic HIV vaccine will likely need to induce
CD4+ and CD8+ T cell responses against multiple antigens to be
effective in humans infected with diverse HIV subtypes. We
hypothesized that a vaccine capable of enhancing these responses
in the gut associated lymphoid tissues (GALT) would be critical for
effective immunotherapy because it would target the primary site
of virus production. Toward this end, we constructed a PMED
SIV DNA vaccine consisting of a plasmid expressing codon-
optimized RT, Nef, and Gag from SIV (17E-Fr) [23] as a single
fusion protein co-delivered with a second plasmid expressing
SIVgp120 (Fig. 1A). To enhance mucosal responses, a third
plasmid was included that expressed a mucosal adjuvant consisting
of the A and B subunits of E.coli enterotoxin (LT) [24,25,26]
(Fig. 1A). We previously showed this adjuvant substantially
increased CD4+ and CD8+ T cell responses when compared to
responses induced by unadjuvanted PMED DNA vaccines [26].
Macaques were infected intravenously with SIV/DeltaB670, a
highly pathogenic primary isolate that induces AIDS in most
rhesus macaques within 5–17 months post-infection with a mean
time to AIDS of 11 months [27]. Because the consensus sequence
of env in the SIV/DeltaB670 inoculum is 15% divergent from the
env sequence in the vaccine [23], this study mimics therapeutic
immunization of humans infected with diverse variants within a
given HIV subtype.
ART (PMPA+lopinavir/ritonavir) was initiated six weeks post-
infection (Fig. 1B). Macaques infected with SIV/DeltaB670
exhibit more rapid immune dysfunction, disease progression,
and shorter survival time when compared to humans infected with
HIV [28,29,30,31], As such, initiating ART 6 weeks post-infection
with SIV is analogous to initiating HAART in HIV-infected
humans at later time points during the chronic stage of infection.
In both situations, the viral setpoint has occurred and disease
progression, defined by progressive declines in CD4 lymphocytes,
is evident. In this study, by 6 weeks post-infection, the viral
setpoint was reached and animals were already exhibiting a mean
33% loss in CD4 counts relative to baseline levels.
All animals received ART alone for 12 weeks (weeks 6–18) to
allow the drugs to establish maximum suppression of viremia prior
to vaccination (Fig. 1B). During weeks 18–38 of the study, each
group continued to receive uninterrupted ART plus 6 monthly
doses of either a PMED SIV DNA vaccine (SIV RT-nef-gag+env)
alone (DNA group, N= 14) or co-delivered with LT (DNA+LT
group, N=14) or empty plasmid (CONTROL group, N= 13).
ART was then withdrawn 6 weeks after the final immunization
(week 45 post-infection), and the effect of each vaccine on virus-
specific immunity, virus burden, prevention of viral rebound, and
protection from AIDS for 5 and 10 months after stopping ART
was determined (Fig. 1B).
Antiretroviral drug therapy with PMPA and Kaletra
affords a highly variable impact on virological control in
SIV-infected macaques
Similar to previous studies [7,32], the virological response to
ART even before the vaccinations were started was highly variable
with only 20 of the 41 animals showing suppression of plasma viral
load within 12 weeks after starting ART (ART responders,
Fig. 2A). The remaining 21 macaques showed little or no response
to ART (ART low responders, Fig. 2A). These animals maintained
persistently high viral loads (.56104) and exhibited ,1 log-fold
reduction in mean viral load during the first 12 weeks of ART
treatment alone (weeks 7–18) when compared to the mean viral
loads measured prior to initiation of ART (weeks 1–6) (Fig. 2B).
The majority of these animals (16/21) were sacrificed prior to
week 66 due to progression to AIDS. In contrast, animals
responding well to ART suppressed viral loads below 104 viral
RNA copies/ml within 12 weeks after starting drugs (Fig. 2A) and
exhibited a 1.6–4.9 log-fold reduction in mean viral load during
ART when compared to pre-ART levels (Fig. 2B). Host and
virological factors that may have influenced the response to ART
in this study are currently under investigation and will be reported
elsewhere. However, we and others have already shown that
therapeutic vaccination is not effective in animals failing ART
[7,32]. Because the goal of this study was to determine the impact
of therapeutic vaccination in combination with an effective ART
regimen, animals failing ART were therefore excluded from this
evaluation. After excluding ART failures, there were 6 animals
remaining in the control group, 7 in the DNA group, and 7 in the
DNA+LT group (Fig. 2B).
DNA vaccines lower viral burden and prevent viral
rebound post-ART
Among ART responders, there were no significant differences
in mean viral loads between the groups before starting ART (week
6) or before initiating the therapeutic vaccinations during ART
(week 18) (Fig. 2C). During the DNA vaccinations and prior to
withdrawing ART, the mean viral load in the DNA+LT group
declined to ,103 copies/ml after the 3rd vaccine dose and
Therapeutic DNA Vaccine for AIDS
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remained below this level by the end of the vaccine/ART
treatment period (week 45) (Fig. 2D). After stopping ART at week
45, mean viral load in the control group increased and reached
.105 copies/ml by the end of the study whereas the mean viral
load in the unadjuvanted DNA vaccine group did not increase
resulting in a 5–15-fold lower viral burden post-ART when
compared to the control group (P= 0.0078) (Fig. 2D). In striking
contrast, the DNA+LT vaccine group continued to maintain mean
viral loads below 103 copies/ml for over 8 months (weeks 47–81)
after stopping ART (Fig. 2C), a level that represents a substantial
2–4 log-fold reduction in mean viral load post-ART when
compared to controls (P = 0.0023)
Containment of viral loads at levels at or below 100 viral RNA
copies/ml for a period of at least 5 months post-ART (weeks 45–66)
was selected as the criterion for therapeutic efficacy in protection
from viral rebound because SIV-infected rhesus macaques that are
elite controllers maintain viremia below this level [33] and because
we previously showed that even transient (i.e. 3–6 months)
containment of viremia below this level after stopping ART
translated to longer-term (.1 year) protection from disease
progression in macaques infected with this virus [32]. Prior to
initiating therapeutic immunizations at week 18, only 2/6 animals
in the control group, 1/7 in the unadjuvanted DNA vaccine group,
and 2/7 in the DNA+LT group had virus loads #100 copies/ml.
After another 37 weeks on ART and the addition of 6 therapeutic
DNA immunizations (weeks 18–45), the number of animals in the
control group with virus loads #100 copies/ml remained
unchanged (2/6) whereas in the DNA and DNA+LT vaccine
groups, the number had increased to 5/7. After ART was stopped,
1/6 (16.7%) animals in the control group, 3 of 7 (42.9%) in the
DNA group, and 6 of 7 macaques (86%) in the DNA+LT group
controlled virus load below 100 copies/ml for a period of at least 5
months post-ART (week 45–66). Furthermore, viremia was
maintained at these very low levels (#100 copies/ml) without
further intervention in all but one animal (R393, DNA+LT group)
for 10 months after stopping ART (until week 88, the duration of
the study). In 5 macaques; including 1 control, 1 in the DNA group,
and 3 in the DNA+LT group; plasma viremia declined to
undetectable levels (,3 copies/ml) by the end of the study.
CD4 counts in the blood paralleled virus burden in plasma in that
most animals showing viral rebound within the first 5 months after
stopping ART exhibited CD4 decline by the end of the study to
levels that were below 50% of the baseline level measured prior to
infection whereas all animals that contained viral rebound for at least
5 months after drug was stopped showed stable CD4+ lymphocyte
counts for the duration of the study (Fig. 3). Interestingly, the
Figure 1. Study Design and DNA vaccines. (A) DNA vaccines. The unadjuvanted DNA vaccine consisted of a co-delivery of 2 plasmids, one
encoding a fusion of SIV RT/Nef/Gag (RNG) and a second encoding SIV gp120 (SIV17E-Fr). The DNA+LT vaccine is a co-delivery of the RNG and
SIVgp120 plasmid and a 3rd plasmid encoding the A and B subunits from the heat-labile enterotoxin of E. Coli (LT) downstream from 2 separate CMV
promoters. The DNA group received 32 mg of the DNA vaccine (16 mg per plasmid) per dose. The DNA+LT group received 32 mg of the DNA vaccine
plus 3.2 mg of the LT genetic adjuvant. (B) Study Design. Anti-retroviral drug therapy (ART) consisting of lopinavir/ritonavir (Kaletra) and PMPA was
started 6 weeks after intravenous infection with SIV/DeltaB670 and continued until week 45 post-infection. Arrows indicate time-points of 6 DNA
immunizations, administered one month apart. Inverted open triangles indicate time-points when a gut jejunal resection was performed and
lymphocytes and tissues isolated for analysis of viral replication, immune responses, and CD4+ T cell counts in the gut. ART was discontinued 7 weeks
after the last DNA immunization to assess the effects of vaccination on protecting against viral rebound and disease. Vaccine efficacy, defined by
containment of viral rebound was assessed at 5 (66 weeks post-infection) and 10 (88 weeks post-infection) months after stopping ART.
doi:10.1371/journal.pone.0033715.g001
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DNA+LT vaccine protected all 7 animals from CD4 decline for the
full duration of the study after stopping ART including 2 animals
that either exhibited early (R428) or delayed (R393) viral rebound
after stopping ART (Fig. 2E). This suggests that transient
containment of viral rebound or other vaccine-induced effects may
afford a therapeutic benefit. Together, these results show that DNA
vaccination during effective ART protected rhesus macaques
chronically infected with SIV from viral rebound and this effect
translated into durable protection from progression to AIDS.
Importantly, the LT adjuvant appears to be a critical component
of this effect since only the DNA+LT vaccine afforded significant
protective efficacy when compared to controls from viral rebound
and/or disease progression after drug was withdrawn (Table 1).
Relationship between TRIM5 or MHC class I haplotypes
and therapeutic outcome
Previous studies have shown that polymorphisms in the viral
resistance factor, TRIM5, can influence susceptibility to SIV
Figure 2. Therapeutic DNA vaccination reduces viral load and protects from viral rebound after drug is stopped. Plasma viral RNA
load was determined by real time RT-PCR. Boxed areas (ART) indicate period of antiretroviral drug therapy. Arrows indicate DNA vaccine doses. (A)
Response to ART (weeks 0–18). Shown are viral loads in 41 SIV-infected macaques before starting ART (weeks 0–6) and during the first 12 weeks of
ART only (weeks 6–18). ART responders (black) had declining viral loads during ART only. ART low responders (red) had little or no decline in viral
loads during ART only and maintained $56104 viral RNA copies/ml (dotted line). (B) Log-fold reduction in viral load during ART only. The change in
viral load during ART in each animal was determined by dividing the mean viral load prior to initiating ART (weeks 4–6) by the mean viral load during
the first 12 weeks of ART but prior to initiating the therapeutic vaccinations (weeks 8–18). Shown is the log-fold reduction in mean viral load during
ART for each animal. ART low responders had ,1 log-fold reduction. ART responders exhibited 1.6–4.9 log-fold reductions in viral load during ART.
(C) Mean plasma viral loads in each group prior to initiating ART (week 6, Pre-ART) and after 12 weeks on ART but before starting therapeutic
vaccinations (week 18, Pre-vaccine). (D) Mean plasma viral loads during vaccinations and after withdrawing ART. Differences in mean viral loads after
withdrawing ART are significant starting at weeks 68 and 48 in the DNA (P = 0.019) and DNA+LT (P = 0.002) groups, respectively, and remained
significant thereafter when compared to controls (Wilcoxon test). (E) Viral loads in each animal. Protection from viral rebound was defined as
containment of viral load #100 viral RNA copies/ml (hashed line) for a period of at least 5 months after drug was withdrawn (weeks 45–66).
doi:10.1371/journal.pone.0033715.g002
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[34,35]. To determine if this host resistance factor influenced our
results, the TRIM5 alleles that have been associated with
intermediate susceptibility (TFP/Q and Q/CypA) or resistance
to SIVmac251 or SIVsmE660 infection (TFP/TFP and TFP/
CypA) were determined. Table 2 shows that 15 of the 20 animals
in this study had either TFP/TFP or TFP/CypA (resistant)
genotypes and the remaining 5 had TFP/Q or Q/CypA
(intermediate susceptibility). Analysis of TRIM5 genotype versus
therapeutic outcome shows that the number of animals with the
resistant TRIM5 genotypes that exhibited elite control of virus was
not significantly different from the number that failed to control
viral rebound (Table 3). This result indicates TRIM5 factors
reported to be associated with enhanced resistance to SIVmac251
or SIVsmE660 do not have a similar influence on the control of
SIV/DeltaB670.
Macaques were also typed for currently known MHC class I
alleles including Mamu-A*01 and Mamu-B*17 that have been
associated with slower disease progression in rhesus macaques
infected with SIVmac239 or mac251 [36]. Among the 4 animals
positive for the A*01 or B*17 alleles, 3 animals (2 positive for A*01
in the DNA group and 1 positive for B*17 in the control group)
failed to control viral rebound after ART was withdrawn
indicating A*01 and B*17 alleles did not provide an advantage
against SIV/DeltaB670 (not shown). This result is consistent with
our previous study where we showed no significant difference in
viral control between A*01 positive and negative rhesus macaques
infected with SIV/DeltaB670 [32].
DNA vaccines increase virus-specific CD4+ and CD8+ T
cell responses, but not antibody responses, in the blood
To determine the impact of the vaccines on the overall magnitude
of the combined CD4/CD8+ T cell response, SIV-specific IFN-c
responses were measured by ELISPOT throughout the study. IFN-c
T cell responses prior to DNA vaccination (week 18) were
comparable between all 3 groups but increased to significantly
Figure 3. Therapeutic DNA vaccination protects from AIDS.Maintenance of CD4+ T cell counts as a marker of clinical disease progression was
measured by flow cytometry. Shown is % CD4+ T cell count relative to baseline. Animals that maintained their CD4+ T cell counts above 50% of their
baseline level (hashed line) level remained clinically healthy throughout the study.
doi:10.1371/journal.pone.0033715.g003
Table 1. Protection from viral rebound and CD4 decline.
Group
Protection from viral
rebound1
Protection from CD4
decline2
#
protected P3
#
protected P3
CONTROLS 1/6 1/6
DNA vs. CONTROLS 3/7 0.559 3/7 0.559
DNA+LT vs.
CONTROLS
6/7 0.025 7/7 0.005
1Containment of plasma viral load#100 RNA copies/ml for a period of at least 5
months (weeks 45–66) after stopping ART
2Maintenance of CD4 counts at or above 50% baseline levels for the duration of
the study after stopping ART
3P values were determined by Fisher’s exact test. After adjusting for 2
comparisons to the control group, a P value of 0.05/2 = 0.025 is considered
significant.
doi:10.1371/journal.pone.0033715.t001
Table 2. Relationship between TRIM5 haplotype and
outcome.
Group Animal Outcome TRIM5
CONTROLS R411 Rebound1 TFP/Q4
R413 Rebound TFP/TFP5
R423 Rebound TFP/TFP
R407 Elite controller2 TFP/TFP
R429 Rebound Q/CypA4
R397 Rebound TFP/Q
DNA R414 Elite controller TFP/TFP
R417 Rebound TFP/TFP
R418 Rebound TFP/Q
R425 Elite controller TFP/Q
R401 Elite controller TFP/TFP
R408 Rebound TFP/TFP
R432 Rebound TFP/TFP
DNA+LT R393 Late rebound3 TFP/CypA5
R395 Elite controller TFP/TFP
R422 Elite controller TFP/TFP
R428 Rebound TFP/TFP
R416 Elite controller TFP/TFP
R426 Elite controller TFP/TFP
R390 Elite controller TFP/TFP
1Rebound: Plasma virus load rebounded to .1000 copies/ml within 26 weeks
after stopping ART.
2Elite Controller: plasma virus load is contained post-ART at #100 copies/ml for
duration of study (44 after stopping ART).
3Late Rebound: Plasma virus load was contained for at least 26 weeks after
stopping ART but rebounded to .1000 copies/ml before end of study.
4TFP/Q and Q/CypA: associated with intermediate susceptibility to SIVmac251
and SIVsmE660 infection (34, 35).
5TFP/TFP and TFP/CypA: associated with resistance to SIVmac251 and
SIVsmE660 infection (34, 35).
doi:10.1371/journal.pone.0033715.t002
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higher levels in both vaccine groups following adminstration of the
2nd (week 24) and 3rd (week 30) DNA vaccine doses. IFN-c T cell
responses then declined but subsequently increased in all 3 groups
after stopping ART (Fig. 4A). Significantly, both vaccine groups
developed higher IFN-c T cell responses after stopping ART than
the controls even though mean virus loads post-ART in the control
group were higher. These results suggest the therapeutic vaccinations
primed the animals to develop a stronger recall T cell response after
ART was stopped.
To determine if therapeutic vaccination influenced antibody
responses, SIVgp120-specific binding antibody was measured at
several time-points throughout the study by ELISA. In contrast to
the T cell response (Fig. 4A) mean antibody responses in both
vaccine groups were lower than in the controls (Fig. 4B).
Neutralizing antibody responses against the vaccine strain (17E-
Fr) measured before (week 40) and 10 weeks after (week 54) ART
was stopped were consistent with the ELISA results in that the
DNA+LT group, which had the lowest mean viral burden, also
had the lowest mean neutralizing antibody response (Fig. 4C). As
expected, higher mean ELISA antibody titers in each animal
positively correlated with higher mean viral loads between weeks
30–88 (P= 0.0206, Spearman’s correlation test), a result that
indicates the level of viral replication and not vaccination, had a
greater influence on the antibody response. Only 3 vaccinated
animals had very low cross-neutralizing antibody against the
challenge strain (B670) either before (week 40) or after stopping
ART (week 54) (Fig. 4D), a result that further indicates serum
antibody likely had little impact on viral control. Despite this
evidence, mucosal secretions were not collected in this study so a
Table 3. Statistical Analysis of Trim5 haplotype versus
outcome.
Phenotype
Intermediate
susceptibility
(TFP/Q or Q/CypA)
Resistance (TFP/TFP
or TFP/CypA)
Outcome Rebound Elite controller Rebound Elite controller
Number of
animals
4/5 1/5 6/15 9/15
P value1 0.206 0.466
12-sided Fisher’s Exact Test.
doi:10.1371/journal.pone.0033715.t003
Figure 4. Therapeutic DNA vaccines increase SIV-specific IFN-c T cell responses, but not antibody, in the blood. (A) IFN-c T cell
responses were measured throughout the study by ELISPOT. Shown is the mean (6 SEM) SIV-specific IFN-c T cell response at each time-point minus
background. Background levels were ,25 SFC/106 PBMC. Differences between the DNA or DNA+LT vaccine groups and controls were significant
(P#0.0063, repeated measures ANOVA). (B) SIV-gp120 specific binding antibody was measured throughout the study by ELISA. Shown are mean (6
SEM) endpoint titers. Mean antibody titers in the DNA+LT group were significantly lower (P = 0.0422) than the controls (C) Neutralizing antibody
responses were measured against the vaccine strain (SIV/17E-Fr). Shown are mean (6 SEM) neutralization titers after the final DNA vaccine dose but
before stopping ART (week 40) and 9 weeks after stopping ART (week 54). *P = 0.0292 (D) Neutralizing antibody titers in each animal before (week 40)
and after (week 54) stopping ART against the challenge strain (SIV/DeltaB670).
doi:10.1371/journal.pone.0033715.g004
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possible role for mucosal antibody in viral control cannot be
entirely excluded.
SIV-specific CD4+ and CD8+ T cell responses were further
characterized in the blood by flow cytometry to determine the
impact of the therapeutic DNA vaccines on separate CD4+ and
CD8+ T cell subsets and on multiple T cell effector functions,
including secretion of IFN-c, TNF-a, and IL-2 cytokines and
expression of CD107a, a marker for cytolytic function [37]. We
focused analysis on responses just before as well as the first 14
weeks after ART was withdrawn (weeks 44–58) to determine if
there was a relationship between T cell responses present shortly
before or after stopping ART and the initial control of viral
rebound. Similar to the IFN-c ELISPOT results, both vaccine
groups developed elevated SIV-specific IFN-c CD4+ (Fig. 5A) and
CD8+ (Fig. 5B) T cell responses by 14 weeks after ART
interruption (week 58). However, after stopping ART, only the
Figure 5. Therapeutic DNA vaccination increases CD4+ and CD8+ T cell responses in the blood after stopping ART. SIV-specific CD4+
and CD8+ T cells with cytokine (IFN-c, TNF-a, IL-2) or cytolytic (CD107a) effector functions were measured in PBMC at 3 time-points just before (week
44) and after (weeks 50, 58) ART was withdrawn by flow cytometry following in vitro stimulation with overlapping peptide pools (RT, Nef, Gag, and
Env) derived from the SIV genes included in the DNA vaccine. Shown is the mean frequency and functional nature of the SIV-specific effector T cell
response in the CD4+ (A) and CD8+ (B) T cell subsets. *indicates P,0.05 in only the DNA+LT group.
doi:10.1371/journal.pone.0033715.g005
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DNA+LT group developed higher frequencies of SIV-specific
CD4+ and CD8+ T cells secreting TNF-a (Fig. 5A and 5B) and
CD8+ T cells expressing the cytolytic marker CD107a (Fig. 5B).
The overall magnitude of the T cell effector response at week 58
was further analyzed by measuring the frequency of SIV-specific T
cells expressing any one of the three cytokines (IFN-c, TNFa, IL-2)
or CD107a. The DNA+LT vaccine had minimal impact on the
CD4+ T cell response but significantly increased SIV-specific
CD8+ T cell responses when compared to controls (P=0.011)
(Fig. 6A). Boolean analysis of co-expression of combined effector
functions showed very few CD4+ (Fig. 6B) or CD8+ T cells
(Fig. 6C) in the blood with more than 2 effector functions.
However, the DNA+LT vaccine significantly increased CD8+ T
cell responses (P = 0.015) with dual effector functions (Fig. 6C).
The DNA+LT vaccine increased SIV-specific CD4+ T cells with
dual TNF-a/IFN-c and TNF-a/IL-2 functions but these trends
fell short of statistical significance (P.0.122, Fig. 6D) and
significantly increased the frequency of CD8+ T cells with dual
TNF-a and cytolytic effector functions (P = 0.033) (Fig. 6E). These
data suggest that viral control after stopping ART in the DNA+LT
group may be due, in part, to enhanced induction of cytotoxic T
lymphocytes with multiple effector functions that are capable of
targeting and eliminating infected cells.
DNA vaccines reduce virus production in lymph nodes
and gut
During ART, lymphoid tissues, particularly those in the GALT,
serve as primary sites for virus production [1]. To determine the
impact of immunization on tissue-associated virus production, full-
length transcripts prepared for packaging into virions were
quantified in mononuclear cells purified from axillary (ALN) and
mesenteric lymph nodes (MLN) and the gut lamina propria (LP) 3
weeks before (week 42) and 3 weeks after (week 48) discontinuing
ART. At both time points, the unadjuvanted DNA vaccine and
DNA+LT vaccine groups showed a 2–3 log-fold reduction in
median virus production in all 3 tissues when compared to the
controls but differences were significant only in the DNA+LT
group (P#0.051) (Fig. 7A). Since viral rebound did not occur in
controls or vaccine failures until after week 52 (Fig. 2E), viral loads
measured in the tissues post-ART at week 48 in each animal were
similar to levels measured prior to stopping ART at week 42
(Fig. 7A). For each animal, the mean viral load in tissues at weeks
42 and 48 strongly correlated (P,0.0013) with the mean plasma
viral load measured after drug was stopped (weeks 48–88) (Fig. 7B).
Importantly, the consistently lower levels of virus production in all
3 tissues of macaques immunized with the DNA+LT vaccine
strikingly corresponded to this vaccine being more effective in
substantially reducing mean viral load and preventing viral rebound
after stopping ART (Fig. 2D and 2E). These results indicate that the
DNA+LT vaccine elicited responses that targeted and reduced virus
persisting in the gut and lymph nodes during ART and suggest that
reducing virus production in the tissues may be important for
protection from viral rebound after cessation of ART.
Viral control correlates with a broader CD8+ T cell
response detectable in the GALT but not the blood
To determine the impact of therapeutic DNA vaccination on
mucosal responses in the GALT, SIV-specific T cell responses in
Figure 6. LT-adjuvanted DNA vaccine increases T cells with multiple effector functions in the blood. SIV-specific T cells with 1–4
cytokine (IFN-c, TNF-a, IL-2) or cytolytic (CD107a) effector functions were measured in PBMC 14 weeks after ART was withdrawn (week 58) by flow
cytometry following in vitro stimulation with overlapping peptide pools derived from genes included in the DNA vaccine (RT, Nef, Gag, Env). Boolean
gating was performed to identify the total frequency of CD4+ and CD8+ T cells in the blood of ART responders with any one of 1–4 effector functions.
(A) Cumulative mean (6SEM) frequency of SIV-specific CD4+ and CD8+ T cells expressing IFN-c, TNF-a, IL-2 or CD107a. Cumulative mean frequency
(6 SEM) of SIV-specific (B) CD4+ and (C) CD8+ T cells co-expressing any combination of 2–4 effector functions. Mean (6 SEM) frequency of SIV-
specific (D) CD4+ and (E) CD8+ T cells expressing the indicated combination of dual effector functions.
doi:10.1371/journal.pone.0033715.g006
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the lamina propria of the small intestine were measured. Because
there was no difference in viral loads at weeks 42 and 48 (Fig. 7A),
mucosal responses measured in each animal at these two time-
points were averaged. The magnitude of the mucosal T cell
response in ART responders was determined by measuring the
frequency of SIV-specific T cells expressing any one of the three
cytokines, IFN-c, TNF-a, IL-2, or the cytolytic marker, CD107a.
Boolean analysis of these effector functions in combination
revealed no significant differences among the three groups in the
frequency of SIV-specific CD4+ or CD8+ effector T cells in the
gut, and very few CD4+ or CD8+ T cells in this compartment
demonstrated more than 2 effector functions (not shown).
However, both vaccines increased IFN-c CD4+ and CD8+ T
cell responses measured by either ELISPOT (Fig. 8A) or
intracellular cytokine staining (ICS, not shown) in the gut when
compared to the controls, but only in the DNA+LT group was this
response statistically significant (P=0.027). These data indicate
that vaccination increased IFN-c T cell responses in the gut but
had no significant impact on the frequency of mucosal CD4+ or
CD8+ T cells with other effector functions.
The breadth of the T cell response in the blood and gut mucosa
against viral antigens included in the vaccine was also measured by
IFN-c ELISpot. T cell responses were mapped against separate
pools of overlapping peptides spanning the entire sequence
encoded by the vaccines and the responses detected against each
peptide pool at weeks 42 and 48 were averaged. No clear
difference in the breadth of the T cell response was observed in the
blood of animals that controlled viral rebound versus noncon-
trollers (Fig. 8B, top panels). The T cell repertoire in the GALT,
however, was strikingly distinct from that observed in the blood.
Animals that failed to control rebound exhibited a limited T cell
repertoire in the GALT against only 1–3 peptide pools; and
responses were dominanted by recognition of Nef (yellow). In
contrast, animals that controlled viral rebound developed a
broader response in the gut against 4–9 peptide pools that were
dominated by responses against Gag (red) (Fig. 8B, lower panels).
This difference was not due to greater preservation of CD4+ T
cells in the gut of the animals that controlled viral rebound because
CD4 counts in the gut at these time-points were similar between
viral rebound controllers and non-controllers (Fig. 8C).
These findings demonstrate that a highly diverse T cell response
localized in the GALT may play an essential role in the prevention
of viral rebound and disease progression post-ART by affording
immune control of virus production within the primary reservoir
of infected cells. To investigate this further, we examined the
correlation between the breadth of the T cell response present in
the blood or gut and mean viral loads in plasma after ART was
stopped (weeks 45–88) or in tissues (weeks 42, 48). Figure 9 shows a
significant correlation between a higher number of peptide pools
recognized by T cells in the gut and lower viral replication in the
plasma post-ART (r =20.703, P= 0.0012, Fig. 9A) or gut lamina
propria (r =20.503, P = 0.0332, Fig. 9B). Similar results were seen
when the breadth of the T cell response in the gut was compared
to viral replication in other compartments including PBMC
(r =20.525, P= 0.0251), axillary lymph node (r =20.490,
P= 0.0392), and mesenteric lymph node (r =20.523, P= 0.0258)
(not shown). In contrast, the breadth of the T cell response in the
blood did not correlate with lower viral loads in blood (Fig. 9C),
the lamina propria (Fig. 9D) or other compartments including
PBMC, axillary and mesenteric lymph nodes (not shown). The
overall magnitude of the IFN-c T cell response determined by
ELISPOT did not correlate with lower viral loads in plasma or
Figure 7. Therapeutic DNA vaccination reduces virus production in the lymph nodes and gut mucosa. (A) Viral load in gut lamina
propria (LP), mesenteric lymph nodes (MLN), and axillary lymph nodes (ALN) in each animal 3 weeks before (week 42, solid circles) and 3 weeks after
ART was withdrawn (week 48, open circles). Solid lines indicate the median viral load for the group. Hashed line indicates the lower limit of detection
for this analysis (3 viral RNA copies). (B) Correlations between mean virus production in the gut lamina propria (left panel), mesenteric lymph nodes
(middle panel) and axillary lymph nodes (right panel) vs. mean plasma viral load in each animal post-ART. Each symbol corresponds to mean virus
load in the plasma of each animal after stopping ART (weeks 47–88) on the X axis vs. mean virus production measured in tissues at weeks 42 and 48
on the Y axis. Spearman’s rank correlation coefficients are shown.
doi:10.1371/journal.pone.0033715.g007
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tissues (r$20.117; P$0.622) (not shown) suggesting that increas-
ing the breadth of the mucosal T cell response against multiple
viral antigens in the gut had more effect on controlling viral
replication than increasing the overall magnitude of the mucosal T
cell response. Taken together, the strong correlation between
protection from viral rebound and a broad specificity in the T cell
repertoire detected in the gut, but not the blood, emphasizes that
immune responses in the gut mucosa may provide a better
correlate of vaccine-induced immunity and therapeutic efficacy.
Discussion
Highly active antiretroviral therapy (HAART) can reduce and
maintain viral load at ,10 HIV-1 RNA copies/ml of plasma
indefinitely. However, HAART does not result in a cure and if
drug treatment is interrupted, virus rebound usually occurs within
weeks. To achieve long-term control of HIV-1 in the absence of
ART (functional cure) or complete eradication of the persistent
virus (cure), new therapies are therefore needed that can be used as
an adjunct to HAART to target the latent HIV-1 and occult viral
reservoirs.
Toward this end, we previously showed that an epitope-based
PMED DNA vaccine administered during PMPA monotherapy
significantly increased T cell responses in the blood of SIV-
infected macaques and induced durable containment of viral
rebound in those animals that responded well to PMPA [32].
However, the positive outcome in this study was likely due, in part,
to initiating drug within two weeks after infection when the
immune system was less compromised.
In the present study, we sought to determine if PMED DNA
immunization would be as effective when drug was initiated later
during chronic infection. In these studies, we also investigated the
impact of co-administering a plasmid expressing the potent
mucosal adjuvant LT (A and B subunits of the heat-labile
enterotoxin from E. coli) with the PMED DNA vaccine to
investigate the hypothesis that increasing virus-specific responses at
the site of the majority of virus production, the gut, would improve
therapeutic efficacy. Consistent with our previous study, we found
that both the unadjuvanted and LT-adjuvanted DNA vaccines
augmented the magnitude of the T cell responses and reduced
viral load in animals that responded well to ART. However,
immunization with the LT-adjuvanted vaccine afforded an
unprecedented 3–5 log-fold reduction in plasma viral load and
superior long-term protection from viral rebound and progression
to AIDS after ART was stopped.
This result is in contrast to previous therapeutic vaccine
approaches tested in macaques as an adjunct to ART during
chronic SIV infection including DNA vaccines administered by
other delivery methods [9,38,39], peptide-pulsed cells [5,6] and
viral vectored vaccines [40]. These approaches afforded only
transient control of initial viral rebound, less than 2 log-fold
reductions in mean viral load post-ART [5,6,9,38,40] or, despite
increasing immune responses, had no impact on virus burden [39].
Although therapeutic outcomes are influenced by a number of
variables such as viral strain, timing of intervention, and
effectiveness of the antiretroviral drugs, our data suggest that the
more profound suppression of virus and durable protection from
viral rebound and disease with the LT-adjuvanted PMED DNA
vaccine may be due to the ability of PMED to induce mucosal
responses [22,41,42] and the effects of LT in augmenting these
responses. Indeed, we found that containment of viral rebound
correlated with a significant reduction in viral replication in the
gut and lymph node reservoirs and the induction of a diverse anti-
viral CD8+ T cell response in the GALT but not the blood, a
finding that provides the first evidence that vaccine induction of
mucosal responses during therapy can target and reduce persistent
virus in the gut.
Both the unadjuvanted and LT-adjuvanted DNA vaccines
similarly increased SIV-specific IFN-c T cell responses in the
blood and gut, but the magnitude of the IFN-c T cell response did
not predict protection from viral rebound. Analysis of other
possible immune effectors of viral control revealed, however, that
improved viral control in the LT-adjuvanted vaccine group
significantly correlated with a broader specificity in the IFN-c T
cell repertoire in the GALT that included increased T cell
recognition of Gag. These results indicate that specificity, rather
than the magnitude, of the IFN-c T cell response may be a more
critical factor for controlling virus production in the mucosa.
Improved viral control in the LT-adjuvanted DNA vaccine
group was also associated with a higher frequency of CD8+ T cells
with dual TNF-a and cytolytic (CD107a) effector functions in the
blood. Direct cytotoxicity was not measured in this study but
expression of CD107a is a marker of degranulation that has been
validated as a reliable surrogate for CD8+ T cells with cytolytic
effector function [37]. The induction of cytolytic effectors is critical
to control of virus because these cells can target and eliminate
persistently infected cells. Consistent with this possibility, prophy-
lactic vaccine studies in rhesus macaques have shown strong
correlations between control of SHIV or SIV infections and CD8+
T cells with a strong cytolytic phenotype but less IFN-c expression
in the blood [43] and mucosa [27,44].
Interestingly, the association between improved viral control in
the DNA+LT group and a higher frequency of CD8+ T cell
responses with dual TNFa/CD107a effector functions was seen in
the blood, but not the gut. In contrast, the broad IFN-c T cell
response in the gut mucosa that correlated with protection from
viral rebound appeared to be sequestered in the gut because the
repertoire differed in specificity from IFN-c T cell responses
measured in the blood at the same time-points. These results show
that immune responses measured in the periphery do not mirror
immune correlates of viral control in the mucosa.
The mechanisms underlying the differential compartmentaliza-
tion of T cell specificity and function in the blood versus gut are
Figure 8. Therapeutic DNA vaccination increases mucosal SIV-specific T cell responses in the gut. (A) The magnitude of the SIV-specific
IFN-c T cell response in the gut was determined by ELISPOT analysis of lamina propria lymphocytes (LPL) isolated from jejunal resections. Results
represent the mean number of IFN-c spot forming cells (6 SEM) for each group from 2 separate experiments performed at 2 time-points post-
infection (weeks 42 and 48). (B) Breadth of the T cell response in each macaque in the blood (top panels, PBMC) and gut (lower panels, GALT). SIV-
specific T cell responses in PBMC and LPL isolated from the jejunum were measured by IFN-c ELISPOT assay against 11 separate pools of overlapping
peptides (15-mers overlapping by 11 amino acids) comprising the indicated amino acid sequences from SIV Gag, Env, Pol, and Nef. The percent
contribution of each peptide-pool specific response to the total response was determined by dividing the mean number of IFN-c spot forming cells
(SFC) measured against each individual peptide pool by the sum of the response against all peptide pools. Results represent the average of 2 time-
points tested at weeks 42 and 48. (C) Mean absolute GALT CD4+ T cell counts measured by flow cytometric analysis of mononuclear cells isolated
from the jejunal lamina propria at weeks 12, 42, and 48 post-infection were similar in animals that controlled vs. failed to control viral rebound after
ART was stopped. Controllers are animals that contained virus at #100 copies for at least 5 months after stopping ART. Non-controllers are animals
that exhibited viral rebound within the same timeframe.
doi:10.1371/journal.pone.0033715.g008
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not known. Following skin immunization, antigen-presenting cells
expressing skin-derived antigen can migrate to the mucosa and
induce T cell responses that remain localized in the gut [45,46]. In
this manner, presentation of skin-derived antigen in the gut would
induce a broader antigen-specific T cell repertoire that would be
distinct from the repertoire in the blood. Furthermore, DNA
vaccines alone or in combination with viral vaccines are known to
increase the breadth [8,32,47] and functional avidity of the T cell
response [48]. These effects, when combined with the fact that
vaccination to the skin induces mucosal immune responses
[24,25,41,45,49,50,51], may act in concert to induce a broad
repertoire of high-avidity CTLs localized in the gut. These
effectors would be more effective in clearing residual virus-infected
cells since high avidity CTLs are known to be more effective than
low avidity CTLs in clearing viral infections [27,46,52,53].
Taken together, the results indicate multiple mechanisms likely
contributed to the enhanced efficacy observed with the LT-
adjuvanted DNA vaccine. The higher frequency of SIV-specific
CD8+ T cell responses with TNF-a and cytolytic effector functions
induced by the LT-adjuvanted DNA vaccine may have contrib-
uted to improved viral control by enhancing clearance of infected
cells. The broader repertoire of SIV-specific T cell responses in the
gut of animals immunized with the LT-adjuvanted vaccine may
have further improved protection from viral rebound by creating a
condition that required selection of an unlikely combination of
multiple viral mutations for the virus to escape immune control.
A control group immunized only with the LT adjuvant was not
included in this study so we cannot rule out the possibility that the
LT adjuvant alone may have stimulated non-specific responses
that enhanced therapeutic efficacy. In mice, we showed LT has
minimal impact on Th2 responses but substantially increases T cell
proliferation and Th1 CD4+ T cell responses with a net outcome
of shifting a Th1/Th2 response to primarily a Th1 response
[26,54]. Thus, LT, whether alone or as an adjuvant to the DNA
vaccine, may improve therapy by increasing virus-specific or
nonspecific Th1 antiviral cytokine responses or by activating
Figure 9. Viral control correlates to CD8+ T cell responses with broad specificity in the gut. Correlations between the breadth of the T cell
response in the gut (top panels A and B) or the blood (lower panels C and D) vs. viral loads in blood (left panels A and C) and gut (right
panels B and D). Each symbol corresponds to mean virus load in the plasma of each animal after stopping ART (weeks 47–88) or gut (weeks 42, 48)
on the X axis vs. mean number of peptide pools recognized in the IFN-c ELISPOT assay at weeks 42 and 48 in the blood or gut lamina propria on the Y
axis. Spearman’s rank correlation coefficients are shown.
doi:10.1371/journal.pone.0033715.g009
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latently-infected CD4+T cells. The residual virus harbored by these
cells would be more susceptible to clearance by the antiretroviral
drugs or by local SIV-specific cytolytic CD8+ T cells induced by the
DNA vaccine. In this setting, effective ART is likely important to
preserve responsiveness to immunization and suppress re-infection
of CD4+ T cells. Additional studies are needed to more precisely
define the immune mechanisms of viral control afforded by the LT-
adjuvanted DNA vaccine and to determine a possible therapeutic
role of the LT adjuvant independent of the vaccine.
The number of animals employed in this study does not
approach the size of efficacy trials in humans, a condition that
raises caution about the interpretation of the outcome of macaque
trials in general. For example, recent studies in macaques have
shown a strong influence of polymorphic Trim5a alleles in SIV
production [35,55]. Other host factors, such as APOBEC and
tetherin, also known to play a role in viral resistance [56], could
influence virus burden. Polymorphic alleles for any one of these
genes could work synergistically with antiretroviral drugs inde-
pendent of the vaccine to suppress virus replication. Haplotyping
of the animals used in this study clearly showed no association of a
particular MHC class I or Trim5a allele with study outcome.
However, we cannot rule out other intrinsic host factors that could
influence the response to drugs and/or vaccines in SIV-infected
macaques [57,58,59,60].
In summary, our findings reiterate the importance of the gut in
HIV infection and pathology [61,62,63] and provide the first
evidence that vaccines capable of inducing mucosal responses may
be able to afford a functional cure by targeting the persistent gut
viral reservoir. The results also support the notion that an effective
therapeutic vaccine could convert HIV-1 infected persons on
highly active antiretroviral drug regimens into elite controllers, a
term used to describe a subset of HIV-1 infected individuals who,
like the macaques protected from viral rebound in this study, can
maintain long-term suppression of viral load at very low levels in
the absence of antiretroviral drugs. It is noteworthy that vaccine-
induced control was achieved despite the use of a highly
pathogenic primary SIV isolate that in infected macaques
produces higher viremia, more rapid progression to AIDS, and
was less effectively inhibited by the antiretroviral drugs used in this
study than in HIV-infected patients undergoing HAART. The
profound impact of vaccination in this setting suggests DNA
vaccines may be able to induce a functional cure in HIV infected
patients even if suboptimal drug regimens insufficiently control
viral replication. Additional studies will be needed to determine
the impact of this vaccine strategy in combination with more
effective antiretroviral drug regimens and initiated at even later
stages in the disease. These findings highlight the potential of a
PMED DNA vaccine as an adjunct to drug therapy to improve
HIV treatment and support further investigation of vaccines that
target the mucosa, in general, as a means to reduce and perhaps
even eradicate persistent viral reservoirs.
Methods
Ethics Statement and animal care
The University of Pittsburgh takes responsibility for humane
care and use of laboratory animals in all research projects
including those awarded by the Public Health Service. They are
committed to comply with the Principles for Use of Animals, the
National Institute of Health Guide for the Care and Use of
Laboratory Animals, the Provisions of the Animal Welfare Act,
and other applicable laws and regulations which are consistent
with the recommendations of the Weatherall report ‘‘The Use of
Non-human Primates in Research’’. The University’s Statement of
Assurance is on file with the PHS, Office for Protection from
Research Risks (A3187-01). The University of Pittsburgh is
accredited by the American Association for the Accreditation of
Laboratory Animal Care International (AAALAC). All experi-
mental manipulations on rhesus macaques were approved by the
University of Pittsburgh’s Institutional Animal Care and Use
Committee (protocol # 0710265). In addition, all studies were
conducted after review by the GlaxoSmithKline (GSK) Institu-
tional Animal Care and Use Committee and in accordance with
the GSK Policy on the Care, Welfare and Treatment of Laboratory
Animals. Animals were cared for by well established, competent
clinical veterinary and animal caretaker staff. All animals received
environmental enrichment throughout this study. All experimental
procedures were performed under ketamine anesthesia and any
discomfort or pain was alleviated by appropriate use of analgesic
agents at the discretion of the attending veterinarian. Health
parameters including CD4 T cell counts, weight, complete blood
analysis, and evidence of opportunistic infection were monitored at
least monthly. Early endpoints of disease were adopted and humane
euthanasia was performed in accordance with guidelines as
established by the 2007 American Veterinary Medical Association
Guidelines on Euthanasia once manifestation of clinical AIDS or
signs of fatal disease were noted.
MHC class I and TRIM5 typing of rhesus macaques
Indian-origin rhesus macaques (Macaca mulatta) were MHC class
I typed for currently known Mamu alleles (A*01, A*02, A*11,
B*08, and B*17) by PCR sequence specific priming and direct
sequencing as previously described [64]. Macaques were typed for
TRIM5 genotypes (TFP, Q, or CypA) that have been associated
with either resistance or intermediate susceptibility to SIVmac251
[35] or SIVsmE660 [34] by PCR amplification of the C-terminal
B30.2/SPRY domain of rhesusTRIM5 utilizing purified genomic
DNA and amplification protocols as described [34]. Resulting
PCR fragments were cloned using the TOPO-TA vector system
(Invitrogen), and TRIM5 sequences for each animal were obtained
from 4–6 clones. Genotypes were determined after alignment with
Geneious software and classified as described [34,55].
Viral challenge and disease progression
Macaques were challenged intravenously with 1 ml of RPMI
containing 100 TCID50 of cryopreserved SIV/DeltaB670 and
monitored for clinical signs of AIDS as described [27]. CD4+ T
cell counts were determined by flow cytometry as described [60].
Anti-retroviral therapy (ART)
Macaques received daily subcutaneous injections of 20 mg/kg
(R)-9-(2-phosphonomethoxypropyl) adenine (PMPA; Gilead Sci-
ences, Foster City, CA) and twice daily oral administrations of
16 mg lopinavir/ritonavir (KaletraH; Abbot Laboratories, Abbott
Park, Illinois) (approximately 13 mg/Kg).
Collection of gut associated tissues
A 15–20 cm section of jejunum and axillary and mesenteric
lymph nodes were surgically removed from each macaque at time-
points indicated in Figure 1B as described [27]. All animals
recovered uneventfully from surgery without post-surgical diarrhea
and weight loss.
Mononuclear cell (MNC) isolation from jejunal resections
and lymph nodes
Mononuclear cells were isolated from fresh lymph nodes and
jejunum (lamina propia lymphocytes or LPL) using a well-
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established enzymatic extraction protocol as previously described
[22,27]. This procedure yields at least 20–806106 cells, a sufficient
number of cells for analysis of both T cell function and specificity.
SIV DNA vaccines
Codon-optimized cDNA of SIV/17E-Fr (Genbank
#AY033146) RT (nucleotides 2852–3117), Nef (nucleotides
9175–9868), Gag p17/27 (nucleotides1053–2142) and gp120
(nucleotides 6604–8895) were used as templates to construct the
vaccine. To reduce potential immunomodulatory effects, RT was
inactivated by mutating W229 to K (W229K), and Nef by removal
of the first 97 amino acids. Contiguous RT-Nef-Gag and gp120
sequences were inserted into the vector cassette, p7313, containing
IE CMV promoter/intronA, a Not I/BamHI multiple cloning site,
the bovine growth hormone poly-adenylation signal, and bacterial
maintenance sequences (GSK, Stevenage, U.K.) to allow expres-
sion of a fusion protein antigen (pSIV-RNG) and gp120 antigen
(pSIV-gp120), respectively (Fig. 1A).
Heat-labile enterotoxin (LT) genetic adjuvant
The plasmid expressing A and B subunits of the Escherichia coli
heat-labile enterotoxin (LT) was previously constructed and tested
for expression as described [26].
Particle-mediated DNA immunization
The pSIV-RNG and pSIV-gp120 plasmids were coated onto
separate gold particles as described [65], and mixed prior to
administration. Macaques were immunized with 32 mg (16 mg
pSIV-RNG and 16 mg pSIV-gp120) co-delivered with or without
3.2 mg of LT into 16 target sites using the PowderJectH XR1 gene
delivery device (PowderJect Vaccines, Inc., Middleton, WI) as
described [66].
Analysis of viral loads in plasma and tissues
Virion-associated RNA in plasma and tissues was quantified by
real time RT-PCR using primers specific for the SIV long terminal
repeat (LTR) as described [22,32]. Cell-associated SIV transcripts
were quantified in Trizol extracted RNA from tissues or purified
mononuclear cells. 250 ng of purified RNA was analyzed by real-
time RT-PCR using forward and reverse primers:probe specific
for the U5 region of 59LTR and the primer binding site. Because
these primers amplify a 92 bp fragment found only in SIV
transcripts prepared for packaging into virions, they can be
considered a reliable indicator of virus production in the tissues.
Forward primer: U5PBSF - GAA ACC GAA GCA GGA AAA
TC; reverse primer: U5PBSR- CTG CCT TCA CTC AGC CGT
ACT, probe: U5PROBE- 6FAM AGG AGT CTC TGA CTC
TCC TTC AAG TCC CTG TT TAMARA. The assay has an
amplification efficiency of 97% and a sensitivity of 3 copies/
reaction.
IFN-c ELISpot assay
IFN-c ELISpot assay was performed following stimulation of
purified mononuclear cells with pools of 15mer peptides
overlapping by 11 amino acids spanning SIV Gag, RT, Nef,
and Env as previously described [8,32]. Responses significantly
higher than background levels (twice the number of IFN-c spot
forming cells or SFC from untreated PBMC plus 10 spots) were
considered positive.
Intracellular cytokine staining assay
Multiparameter intracellular cytokine staining (ICS) assays were
performed on mononuclear cells stimulated with peptide pools
spanning SIV gag and env as previously as described [42,67]. Cells
were stained with the following antibodies (BD Biosciences, San
Jose, CA): CD3-Pacific BlueTM (rhesus, cloneSP34-2); CD8-APC-
Cy7 (rhesus, clone RPA-T8), CD4-PerCP (rhesus, clone L200),
FITC-CD107a/b (human clones H4A3, H4B4), PE-IL-2 (human,
clone MQ1-17H12), APC-TNFa (rhesus, clone MAb11), and PE-
Cy7-IFN-c (human, clone 4S.B3) and analyzed using an LSR II
flow cytometer (BD Biosciences) and FlowJo software (Tree Star,
Inc., Ashland, OR). Events were subjected to a lymphocyte gate by
a forward scatter versus SSC. Live T cells were identified by a
live/dead versus CD3+ plot. Following identification of CD8+ and
CD4+ T cells, a gate was made for each function and a Boolean
gate platform was used to create all possible combinations. All data
are reported after subtraction of background staining of unstimu-
lated cells obtained at the same timepoint. Background levels from
unstimulated cells or cells stimulated with irrelevant peptide
(HBsAg) typically ranged from 0.04–0.18% for single effector
function analysis and 0.00–0.03% for multiple (2–4) functions.
Baseline single function responses (week 0, prior to infection) in
each macaque ranged from 20.06–0.04%.
Analysis of antibody responses
SIV-gp120 specific IgG binding antibody titers were measured
by enzyme-linked immunosorbance assay (ELISA) as described
using recombinant SIVmac239 gp120 for capture antigen
(Intracel, Issaquah, WA) and a rabbit anti-IgG (heavy and light
chains conjugated to alkaline phosphatase (Accurate Chemical,
Westbury, NY) to detect antibody bound to the capture antigen
[22]. Viral neutralization titers were determined as described [68].
Briefly, serial dilutions of plasma from vaccinated animals were
incubated with 200 TCID50 of the SIV isolates 17E-Fr or Delta-
B670 and incubated for 1 hour before addition to Tzm-bl cells.
After 48 hours, the levels of infection were determined using
Bright-Glo reagents (Promega, Madison, WI) and measurement of
relative light units. The neutralizing titer was identified as the
reciprocal of the highest plasma dilution able to inhibit virus
infection by 70% as compared to virus controls. Neutralization
titers were confirmed in duplicate assays.
Statistical analyses
Statistical comparisons of protection from viral rebound, viral
loads in tissues and blood, and mucosal and systemic immune
responses were performed between each vaccine group and the
controls using GraphPad Prism statistical software. The primary
endpoints for comparing therapeutic efficacy between vaccinated
animals and controls were protection from viral rebound, as
defined by containment of viral loads in plasma ,100 viral RNA
copies/ml for a period of at least 5 months (21 weeks) after
stopping ART and protection from progression to AIDS as
defined by maintenance of CD4 counts above 50% of the baseline
pre-infection levels for the duration of the study. Differences in
protection from viral rebound and/or CD4 decline between
groups were determined by one-sided Fisher’s exact test.
Differences in serial measurements of viral RNA loads in plasma
or T cell responses between each vaccine group and controls were
determined by two-sided Wilcoxon rank-sum test and repeat
measures ANOVA, respectively. Differences between mean viral
RNA loads in gut and lymph node tissues or T cell responses at
individual time points were determined by two-sided Mann-
Whitney to compare 2 groups or one-way ANOVA and Kruskal-
Wallis post-test to compare 3 groups. Correlations between virus
loads in tissues and plasma or between immune responses and
virus loads in tissues or plasma were determined by Spearman’s
rank correlation test. A significance threshold of 0.05 was used for
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each statistical test and, where appropriate, adjustments for
multiple comparisons were made.
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